Tessel Biosciences

Tessel Biosciences is a private, pre-clinical stage biotech based in Boston, combining a 'virtual tissues' platform with AI to design real drugs. The company is developing a pipeline targeting the causes and consequences of tissue remodeling, starting with lung diseases, by using its proprietary Tesselogic platform to run optimized experiments on patient-derived tissues. Led by a technically strong team with backgrounds from MIT, Harvard, and top AI/drug discovery firms, Tessel appears to be pre-revenue and focused on platform validation and early pipeline advancement. Its approach aims to bridge the gap between complex human biology and scalable, causal drug discovery.

Tesselogic: An integrated platform combining patient-derived organotypic tissue models (e.g., lung tissues that exhibit physiological functions like mucus transport) with active learning AI algorithms. The platform runs optimized experiments to causally map molecular state to tissue function for efficient target and drug discovery.

Tessel competes in the crowded AI/ML drug discovery sector with companies like Recursion, Exscientia, and Insilico Medicine. Its key claimed differentiation is the deep integration of physiologically functional human tissue models with its AI, moving beyond purely molecular or cellular data. However, it faces competition from both pure-play AI biotechs and large pharma's internal digital R&D efforts.